Pharma BD Deal Intelligence
AbbVie acquired Cerevel Therapeutics for $8.7B for neuroscience pipeline expansion.
AbbVie is buying neuroscience biotech Cerevel Therapeutics for $8.7 billion in cash, just a day after announcing a $10.1 billion purchase of ADC specialist…
AbbVie's $8.7 billion Cerevel acquisition took a major hit Monday after emraclidine failed to separate from placebo in both EMPOWER-1 and EMPOWER-2 Phase…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
AbbVie acquired Cerevel Therapeutics for $8.7B for neuroscience pipeline expansion.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Cerevel Therapeutics (this deal) | 2023 | $8.7B | 31 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2023 deals · AbbVie Inc. deals · Neurology deals